Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2

    June 2023 in “ British Journal of Dermatology ”
    Paul Farrant, Alexander Egeberg, Taisuke Ito, Beatrice Gittens, Chiara Chiasserini, Guanglei Yu, Frédérick Durand, Yu‐Huei Huang
    From the encyclopedia
    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks. Our plain-language summary of this paper — not a Tressless recommendation.
    The study "P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2" evaluated the effectiveness of baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, in treating severe alopecia areata (AA) over 52 weeks. The study included 855 patients who were randomized to receive either 2mg or 4mg of baricitinib. The severity of AA was categorized as severe (SALT score 50–94) or very severe (SALT score 95–100). At week 52, a SALT score ≤ 20 was achieved by 36.1% and 51.2% of patients on baricitinib 2mg and 4mg, respectively, with severe AA and 12.4% and 27.7% of patients on baricitinib 2mg and 4mg, respectively, with very severe AA. The study concluded that baricitinib showed efficacy in treating both severe and very severe AA, with similar proportions of patients achieving full coverage or minimal gaps in eyebrows and eyelashes at week 52, regardless of scalp hair-loss severity.
    Discuss this study in the Community →